Myolimus

Drug Profile

Myolimus

Alternative Names: Myolimus-eluting stent

Latest Information Update: 28 Mar 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Elixir Medical Corporation
  • Class Cardiovascular therapies; Lactones; Macrolides
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Coronary artery restenosis

Most Recent Events

  • 17 May 2012 Elixir Medical Corporation completes the DESolve-I phase I trial in Coronary artery restenosis (prevention) in Belgium and New Zealand (NCT02086006)
  • 16 May 2012 Interim adverse events data from a phase I trial in Coronary artery restenosis (prevention) released by Elixir Medical
  • 29 Oct 2008 Phase-I clinical trials in Coronary artery restenosis (prevention) in Belgium (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top